10-Q: Nexalin Technology Reports Q1 2025 Results: Revenue Declines Amidst Increased R&D Spending

Nexalin Technology's Q1 2025 results show a decrease in revenue compared to Q1 2024, coupled with increased operating expenses, particularly in research and development.

Summary

• Nexalin Technology, Inc. reported its financial results for the quarter ended March 31, 2025.
• The company designs and develops neurostimulation products for mental health conditions.
• Net revenue for Q1 2025 was $41,015, a decrease from $78,671 in Q1 2024.
• The decrease in revenue is primarily due to lower device sales compared to the previous year.
• Operating expenses increased to $2,038,682 in Q1 2025 from $1,143,227 in Q1 2024.
• This increase was driven by higher professional fees, selling, general, and administrative expenses, and research and development costs.
• Research and development expenses rose significantly due to the development of the Gen-2 and Gen-3 devices.
• The company reported a net loss of $1,988,337 for Q1 2025, compared to a net loss of $1,041,157 for Q1 2024.
• As of March 31, 2025, Nexalin had cash and cash equivalents of $622,029.
• The company has a significant accumulated deficit of $86.7 million.
• Nexalin's ability to continue as a going concern depends on obtaining U.S. approval for its devices and raising additional capital.
• A public offering of 3,850,000 shares of common stock was completed on May 6, 2025, resulting in gross proceeds of approximately $5,005,000.
• The company is pursuing FDA clearance for its Gen-2 SYNC and Gen-3 HALO devices and plans to conduct clinical trials.
• Nexalin is also developing a virtual clinic platform for remote patient monitoring and treatment.

Sentiment

Score: 3

Explanation: The sentiment is negative due to declining revenue, increasing losses, and concerns about the company's ability to continue as a going concern. While there are some positive developments, such as regulatory approvals and a recent capital raise, the overall financial picture is concerning.

Positives

• The company is actively pursuing FDA clearance for its next-generation devices, Gen-2 SYNC and Gen-3 HALO.
• Nexalin is developing a virtual clinic platform to improve accessibility and reduce the stigma associated with mental health treatment.
• The company completed a public offering on May 6, 2025, raising approximately $5,005,000, which should provide additional working capital.
• The company's Gen-2 device has received regulatory approval in Brazil and conditional approval in Oman.
• The company is developing a Military & Government Advisory Board aimed at fostering and enhancing relationships within and throughout United States federal government and public sector organizations.

Negatives

• Revenue decreased significantly in Q1 2025 compared to Q1 2024.
• Operating expenses increased substantially, leading to a larger net loss.
• The company has a significant accumulated deficit and negative cash flows from operations.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company has been notified of non-compliance with Nasdaq's minimum bid price requirement in the past.

Risks

• The company's ability to obtain FDA clearance for its Gen-2 and Gen-3 devices is uncertain.
• The company's continued listing on the Nasdaq Capital Market is subject to meeting minimum financial and other requirements.
• The company's success depends on the acceptance of its devices by healthcare providers, physicians, clinicians, patients, and third-party payors.
• The company faces competition from other therapies and treatments for mental health conditions.
• The company's intellectual property may not be adequately protected.
• The company may not be able to raise additional capital when needed.
• The company has material weaknesses in internal controls.

Future Outlook

The company expects to continue to incur operating losses as it executes its development plans through 2025 and beyond. The company's ability to continue as a going concern is dependent upon its ability to obtain U.S. approval for the sale of its devices and, if necessary, its ability to raise additional capital. The company plans to develop a strategic schedule to execute additional pilot trials and/or pivotal trials for the new Gen-3 HALO device for anxiety and insomnia in the United States, Brazil and China beginning in the third or fourth quarter of 2025.

Industry Context

Nexalin operates in the neurostimulation and mental health technology sector, which is experiencing growth due to the increasing prevalence of mental health disorders and the demand for non-pharmacological treatments. The company's focus on innovative bioelectronic medical technologies aligns with the industry trend towards personalized and accessible mental healthcare solutions. The development of a virtual clinic platform also reflects the growing adoption of telehealth in mental health services.

Comparison to Industry Standards

• It is difficult to compare Nexalin's results directly to industry standards due to its unique technology and stage of development.
• Companies like Neuronetics, which focuses on TMS (Transcranial Magnetic Stimulation), and electroCore, which develops vagus nerve stimulation devices, operate in related but distinct segments of the neuromodulation market.
• Compared to these companies, Nexalin is smaller in terms of revenue and market capitalization.
• The company's success will depend on its ability to secure regulatory approvals, demonstrate clinical efficacy, and commercialize its products effectively.
• The company's high operating expenses and net losses are typical for early-stage medical device companies investing heavily in research and development.
• The company's focus on a virtual clinic model is similar to trends seen in other telehealth companies, such as Teladoc Health and Amwell, which are expanding their services to include mental health support.

Management Changes

Legal Proceedings

• Sarah Veltz v. Nexalin Technology, Inc. et al.: A settlement agreement has been reached, and the case is expected to be dismissed with prejudice.
• The Company is currently engaged in settlement discussions with the Employment Development Department (EDD) of the State of California.

Related Party Transactions

• The company has a consulting agreement with U.S. Asian Consulting Group, LLC, whose members are shareholders in the Company.
• Wider Come Limited (Wider), a related party, is obligated to fund all operations for the initial 12-month period of the Joint Venture, after which Nexalin and Wider plan to jointly fund the Joint Ventures operating expenses in accordance with their pro rata ownership.

Stakeholder Impact

• Shareholders: The declining financial performance and concerns about the company's ability to continue as a going concern could negatively impact shareholder value.
• Employees: The company's financial challenges could lead to cost-cutting measures, including potential layoffs.
• Customers: The company's ability to continue providing services and support for its existing devices may be affected by its financial situation.
• Suppliers: The company's ability to pay its suppliers on time could be impacted by its financial challenges.
• Creditors: The company's ability to repay its debts could be affected by its financial challenges.

Next Steps

• Pursue FDA clearance for Gen-2 SYNC and Gen-3 HALO devices.
• Conduct clinical trials for Gen-2 SYNC and Gen-3 HALO devices.
• Develop and launch the virtual clinic platform.
• Execute pilot trials and/or pivotal trials for the new Gen-3 HALO device for anxiety and insomnia in the United States, Brazil and China beginning in the third or fourth quarter of 2025.
• Continue discussions with the EDD and have presented a settlement offer.

Key Dates

Keywords

Nexalin, neurostimulation, mental health, FDA clearance, Gen-2 SYNC, Gen-3 HALO, clinical trials, virtual clinic, financial results, revenue, operating expenses, net loss, Nasdaq, going concern, capital raise